Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 3961-3968

  Kumeda, Shin Ichiro ^a   Deguchi, Atsuko ^a   Toi, Masakazu ^b   Omura, Satoshi ^c   Umezawa, Kazuo ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c NONE

Author keywords

Angiogenesis; p21(WAF1 CIP1); p53; Proteasome

Indexed keywords

AMINOPEPTIDASE; BASIC FIBROBLAST GROWTH FACTOR; CYCLOHEXIMIDE; CYSTEINE PROTEINASE; FUMAGILLOL CHLOROACETYLCARBAMATE; LACTACYSTIN; N ACETYLLEUCYLLEUCYLNORLEUCINAL; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P53; PROTEINASE; SERINE PROTEINASE;

ANGIOGENESIS; ARTICLE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENDOTHELIUM CELL; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SERUM; UMBILICAL VEIN;

EID: 0032764099     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Yancopoulos GD, Klagsbrun M, and Folkman J: Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 93: 661-664, 1998.
2. Folkman J, and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
3. Fujimoto J, Hori M, Ichigo S, and Tamaya T: Sex steroids regulate the expression of plasminogen activator inhibitor-1 and its mRNA in fibroblasts derived from uterine endometrium. Ann Clin Biochem 33: 545-550, 1996.
4. Ashino-Fuse H, Takano Y, Oikawa T, Shimamura M, and Iwaguchi T: Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer 44: 859-864, 1989.
5. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, and Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 555-557, 1990.
6. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, and Fujita T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470: AGM-1470). Cancer Res 53: 4262-4267, 1993.
7. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, and Liu JO: Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 4: 461-471, 1997.
8. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, and Crews CM: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase MetAP-2. Proc Natl Acad Sci USA 94: 6094-6103, 1997.
9. Umezawa H: Enzyme Inhibitors of Microbial Origin. University of Tokyo Press, Tokyo, 1972.
10. Umezawa K, and Aoyagi T: Elimination of protein degradation by use of protease inhibitors. Receptor Purification Procedures, Alan R. Liss Inc New York: 139-148, 1984.
11. Goldberg AL: The mechanism and functions of ATP-dependent proteases in bacterial and animal cells. Eur J Biochem 203: 9-23, 1992
12. Hershko A, and Ciechanover A: The ubiquitin system for protein degradation. Annu Rev Biochem 61: 761-807, 1992.
13. Coux O, Tanaka K, and Goldberg AL: Structure and functions of the 20 S and 26 S proteasomes. Annu Rev Biochem 65: 801-847, 1996
14. Glotzer M, Murray AW, and Kirschner MW: Cyclin is degraded by the ubiquitin pathway. Nature 349: 132-138, 1991.
15. Clurman BE, Sheaff RJ, Thress K, Groudine M, and Roberts JM: Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10: 1979-1990, 1996.
16. Seufert W, Futcher B, and Jentsch S: Role of a ubiquitin-conjugating enzyme in degradation of S- and M- phase cyclins. Nature 373: 78-81, 1995.
17. Maki CG, Huibregtse JM, and Howly PM: In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 56: 2649-2654, 1996.
18. Blagosklonny MV, Wu GS, Omura S, and El-Diery WS: Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 227: 564-569, 1996.
19. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, and Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27. Science 269: 682-685, 1995.
20. Katagiri M, Hayashi M, Matsuzaki K, Tanaka H, and Omura S: The neuritogenesis inducer lactacystin arrests cell cycle at both G0/G1 and G2 phases in Neuro 2a cells. J Antibiot 48: 344-346, 1995.
21. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, and Schreiber SL: Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 265: 726-731, 1995.
22. Chang YC, Lee YS, Tejima T, Tanaka K, Omura S, Heintz NH, Mitsui Y, and Magae J: mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 9: 79-84, 1998.
23. Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar LJ, and Castronovo V: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54: 2073-2076, 1994.
24. WAF1/CIP1 induction, G2/M arrest, and apoptosis. Exp Cell Res 241: 394-403, 1998.
25. Fattman CL, An B, Sussman L, and Dou QP: p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Cancer Lett 130: 103-113, 1998
26. Ge X, Yannai S, Rennert G, Gruener N, and Fares FA: 3,3'-Diindolymethane induces apoptosis in human cancer cells. Biochem Biophys Res Commun 228: 153-158, 1996.
27. Aoyagi T, Miyata S, Nanbo M, Kojima F, Matsuzaki M, Ishizuka M, Takeuchi T, and Umezawa H: Biological activities of leupeptins. J Antibiot (Tokyo) 22: 558-568, 1969.
28. Saito D, Sawamura M, Umezawa K, Kanai Y, Furihata C, Matsushima T, and Sugimura T: Inhibition of experimental blood-borne lung metastasis by protease inhibitors. Cancer Res 40: 2539-2542, 1980.
29. Umezawa H, Ishizuka M, Aoyagi T, and Takeuchi T: Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo), 29: 857-859, 1979.
30. Freitas JO Jr, Termignoni C, Guimaraes JA: Microsomal methionine aminopeptidase: properties of the detergent- solubilized enzyme. Int J Biochem 17: 1285-1291, 1985.
31. Takahashi S, Ohishi Y, Kato H, Noguchi T, Naito H, and Aoyagi T: The effect of bestatin, a microbial aminopeptidase inhibitor, on epidermal growth factor-induced DNA-synthesis and cell division in primary cultured hepatocytes of rats. Exp Cell Res 183: 399-412, 1989.
32. Ciechanover A, DiGiuseppe JA, Bercovich B, Orian A, Richter JD, Schwaltz AL, and Brodeur GM: Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci USA 88: 139-143, 1991.
33. Treier M, Staszewski LM, and Bohmann D: Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain. Cell 78: 787-798, 1994.
34. Palombella VJ, Rando OJ, Goldberg AL, and Maniatis T: The ubiquitin-proteasome pathway is required for processing the NFkB 1 precursor protein and the activation of NFkB. Cell 78: 773-785, 1994
35. Rolfe M, Beer-Romero P, Glass S, Eckstein J, Berdo I, Theodoras M, Pagano M, and Draetta G: Reconstitution of p53 ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6-AP). Proc Natl Acad Sci USA 92: 3264-3268, 1995.
36. Scheffner M, Huibregtse JM, and Howley PM: Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci USA 97: 8797-8801, 1994.
37. Hateboer G, Kerkhoven RM, Shvarts A, Bernards R, and Beijersbergen RL: Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev 10: 2960-2970, 1996.
38. Hofmann F, Martelli F, Livingston DM, and Wang Z: The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev 10: 2949-2959, 1996.
39. Mellgren RL: Evidence for participation of a calpain-like cysteine protease in cell cycle progression through late G1 phase. Biochem Biophys Res Commun 236: 555-558, 1997
40. Mutomba MC, To WY, Hyun WC, and Wang CC: Inhibition of proteasome activity blocks cell cycle progression at specific phase boundaries in African trypanosomes. Mol Biochem Parasitol 90: 491-504, 1997.
41. DeCaprio JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Piwnica-Worms, H, Huang C-M and Livingston DM: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 63: 1085-1095, 1989.
42. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
43. Chowdary DR, Dermody JJ, Jha KK, and Ozer HL: Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 14: 1997-2003, 1994.
44. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, and McMahon M: Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21CIP1. Mol Cell Biol 17: 5598-5611, 1997.
45. Koyama H, Nishizawa Y, Hosoi M, Fukumoto S, Kogawa K, Shioi A and Morii H: The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-1. Possible involvement of cyclin-dependent kinase 2. Circ Res 79: 757-764, 1996.